XML 29 R18.htm IDEA: XBRL DOCUMENT
v3.21.2

Stock-Based Compensation Expense | 6 Months Ended
--- | ---
Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Stock-Based Compensation Expense | 11. Stock-Based Compensation Expense During the six months ended June 30, 2021, the Company granted the following awards:
|  | Three Months Ended |  |  | Three Months Ended |  |  | Six Months Ended |
|  | March 31, 2021 |  |  | June 30, 2021 |  |  | June 30, 2021 |
Employee awards: |  |  |  |  |  |  |  |  |  |  |  |
RSUs |  |  | 370,137 |  | (1) |  | 1,476,059 |  | (2) |  | 1,846,196 |
Market RSUs |  |  | — |  |  |  | 918,775 |  | (3) |  | 918,775 |
Non-employee director RSUs |  |  | — |  |  |  | 316,232 |  | (4) |  | 316,232 |
Total awards |  |  | 370,137 |  |  |  | 2,711,066 |  |  |  | 3,081,203 |
____________________
(1) | RSUs had a weighted average grant date fair value of $5.53 per share, of which 202,237 RSUs had a vesting period of 1 year and 167,900 RSUs had a vesting period of four years.
(2) | RSUs had a weighted average grant date fair value of $4.26 per share and a vesting period of 4 years.
(3) | Market RSUs had a grant date fair value of $9.30 per share and will vest on May 17, 2024 provided the closing price of the Company’s common stock on such vesting date is not less than the closing price on May 17, 2021. The number of shares delivered on the vesting date is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 18, 2021 until May 17, 2024 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.
(4) | RSUs had a weighted average grant date fair value of $4.31 per share and vested immediately upon grant, but the underlying shares of common stock will not be delivered until there is a separation of service, such as resignation, retirement or death.
As of June 30, 2021, there was $3.4 million of unrecognized stock-based compensation expense related to options and PNQs, which is expected to be recognized over a weighted average period of approximately 1.6 years, and $12.6 million and $12.5 million of unrecognized stock-based compensation expense related to RSUs and Market RSUs, respectively, which is expected to be recognized over a weighted average period of approximately 3.4 and 2.6 years, respectively. Total stock-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended June 30, 2021 and 2020 was as follows (in thousands):
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
RSUs and options |  | $ | 3,819 |  |  | $ | 2,122 |  |  | $ | 5,625 |  |  | $ | 3,188 |
Employee stock purchase plan |  |  | 107 |  |  |  | 63 |  |  |  | 236 |  |  |  | 125 |
Total stock compensation expense |  | $ | 3,926 |  |  | $ | 2,185 |  |  | $ | 5,861 |  |  | $ | 3,313 |
Employee Stock Purchase Plan The Company provides all employees, including executive officers, the ability to purchase our common stock at a discount under our 2004 employee stock purchase plan (the “ESPP”). The ESPP is designed to comply with Section 423 of the Internal Revenue Code and provides all employees with the opportunity to purchase up to $25,000 worth of our common stock (based on the undiscounted fair market value at the commencement of the offering period) each year at a purchase price that is the lower of 85% of the fair market value of the common stock on either the date of purchase or the commencement of the offering period. An employee may not purchase more than 5,000 shares of common stock on any purchase date. The executives’ rights under the ESPP are identical to those of all other employees. The Company issued 292,981 and 333,727 shares of common stock pursuant to the ESPP for the six months ended June 30, 2021 and 2020, respectively. There were approximately 1.3 million shares of common stock available for issuance under the ESPP as of June 30, 2021.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration